The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
|Articles|January 20, 2022
Daily Medication Pearl: Cyclosporine Ophthalmic Solution (Cequa)
Author(s)Saro Arakelians, PharmD
Cequa ophthalmic solution is indicated to increase tear production in patients with dry eyes.
Advertisement
Medication Pearl of the Day: Cyclosporine ophthalmic solution (Cequa)
Indication: Cequa ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eyes).
Insight:
- Dosing: Instill 1 drop of Cequa twice daily (approximately 12 hours apart) into each eye. Discard the vial immediately after using in both eyes.
- Dosage forms: Ophthalmic solution containing cyclosporine 0.9 mg/mL.
- Adverse events (AEs): The most common AEs reported in greater than 5% of subjects were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other AEs reported in 1% to 5% of the patients were blepharitis, eye irritation, headache, and urinary tract infection.
- Mechanism of action: Cyclosporine is a calcineurin inhibitor immunosuppressant agent when administered systemically.
- Manufacturer: Sun Pharma
Sources:
Advertisement
Related to this article
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
3
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5